TGF-β regulates invasive behavior of human pancreatic cancer cells by controlling Smad expression

Archives of Medical Science

Volumn 3, Issue 3, 2007, Pages 185-191

  Sawai, Hirozumi ^a   Yasuda, Akira ^a   Ochi, Nobuo ^a   Takahashi, Hiroki ^a   Wakasugi, Takehiro ^a   Azuma, Masaaki ^a   Matsuo, Yoichi ^a   Funahashi, Hitoshi ^a   Sato, Mikinori ^a   Akamo, Yoshimi ^a   Takeyama, Hiromitsu ^a   Manabe, Tadao ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Growth factor; Pancreatic cancer; Tumor invasion

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTIBODY; BETA ACTIN; MATRIGEL; MESSENGER RNA; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CARCINOGENESIS; CELL ACTIVATION; CELL COUNT; CELL PROLIFERATION; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 35449005284     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Li D, Xie K, Wolff R, Abruzzese JL. Pancreatic cancer. Lancet 2004; 363:1049-57.
2. Chua YJ, Cunningham D. Adjuvant treatment for resectable pancreatic cancer. J Clin Oncol 2005; 23:4532-7.
3. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-10.
4. Peng B, Fleming JB, Breslin T, et al. Suppression of tumorigenesis and induction of p15ink4b by Smad4/DPC4 in human pancreatic cancer cells. Clin Cancer Res 2002; 8: 3628-38.
5. Sawai H, Funahashi H, Yamamoto M, et al. Interleukin-1alpha enhances integrin alpha(6)beta(1) expression and metastatic capability of human pancreatic cancer. Oncology 2003; 65:167-73.
6. Shirk AJ, Kuver R. Epidermal growth factor mediates detachment from and invasion through collagen I and Matrigel in Capan-1 pancreatic cancer cells. BMC Gastroenterol 2005; 5: 12.
7. El Fitori J, Kleeff J, Giese NA, et al. Melanoma Inhibitory Activity (MIA) increases the invasiveness of pancreatic cancer cells. Cancer Cell Int 2005; 5: 3.
8. Xu G, Chakraborty C, Lala PK. Expression of TGF-beta signaling genes in the normal, premalignant, and malignant human trophoblast: loss of Smad3 in choriocarcinaoma cells. Biochem Biophys Res Commun 2001; 287:47-55.
9. Fukuda H, Motohiro T, Nakai K, et al. Negative effect of transforming growth factor-beta-1 on intestinal anastomotic tissue regeneration. Eur Surg Res 2001; 33: 388-94.
10. Geremias AT, Carvalho MA, Borojevic R, Monteiro ANA TGF betal and PDGF AA override collagen type I inhibition of proliferation in human liver connective tissue cells. BMC Gastroenterol 2004; 4: 30.
11. Baldwin RL, Tran H, Karlan BY. Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling. Cancer Res 2003; 63: 1413-9.
12. Suh N, Roberts AB, Birkey Reffey S, et al. Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. Cancer Res 2003; 63: 1371-6.
13. Maliekal TT, Antony ML, Nair A, Paulmurugan R, Karunagaran D. Loss of expression, and mutations of Smad2 and Smad4 in human cervical cancer. Oncogene 2003; 22: 4889-97.
14. Elkak AE, Newbold RF, Thomas V, Mokbel K. Is telomerase reactivation associated with the down-regulation of TGF beta receptor-II expression in human breast cancer? Cancer Cell Int 2003; 3: 9.
15. Woszczyk D, Gola J, Jurzak M, Mazurek U, Mykala-Cieśla J, Wilczok T. Expression of TGF beta1 genes and their receptor types I, II, and III in low- and high-grade malignancy non-Hodgkin's lymphomas. Med Sci Monit 2004; 10: CR33-7.
16. Kleeff J, Korc M. Up-regulation of transforming growth factor (TGF)-beta receptors by TGF-beta1 in COLO-357 cells. J Biol Chem 1998; 273: 7495-500.
17. Kleeff J, Wildi S, Friess H, Korc M. Ligand induced upregulation of the type II transforming growth factor (TGF-beta) receptor enhances TGF-beta responsiveness in COLO-357 cells. Pancreas 1999; 18: 364-70.
18. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-29.
19. Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002; 12: 22-9.
20. Tvrdik D. The effect of TGFbeta1 on the expression and phosphorylation of key cell-cycle regulators in malignant B cells. Med Sci Monit 2004; 10: BR447-54.
21. Johnsen SA, Subramanian M, Janknecht R, Speisberg TC. TGF-β inducible early gene enhances TGF-β/Smad-dependent transcriptional responses. Oncogene 2002; 21: 5783-90.
22. Fu Y, O'Connor LM, Shepherd TG, Nachtigal MW. The p38 MARK inhibitor, PD169316, inhibits transforming growth factor beta-induced Smad signaling in human ovarian cancer cells. Biochem Biophys Res Commun 2003; 310: 391-7.
23. Hamamoto T, Beppu H, Okada H, et al. Compound disruption of Smad2 accelerates malignant progression of intestinal tumors in ape knockout mice. Cancer Res 2002; 62: 5955-61.
24. Nicolas FJ, Hill CS. Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest. Oncogene 2003; 22: 3698-711.
25. Shepard TG, Nachtigal MW. Identification of a putative autocrine bone morphogenetic protein-signaling pathway in human ovarian surface epithelium and ovarian cancer cells. Endocrinology 2003; 144: 3306-14.
26. Kanamaru C, Yasuda H, Fujita T. Involvement of Smad proteins in TGF-beta and activin A-induced apoptosis and growth inhibition of liver cells. Hepatol Res 2002; 23: 211-9.
27. Dunfield LD, Nachtigal MW. Inhibition of the antiproliferative effect of TGF-beta by EGF in primary human ovarian cancer cells. Oncogene 2003; 22: 4745-51.
28. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-beta responses. Cell 1998; 95: 737-40.
29. Hayashi H, Abdollah S, Qiu Y, et al. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 1997; 89: 1165-73.
30. Massague J. TGF-β signal transduction. Annu Rev Biochem 1998; 67: 753-91.
31. Imamura T, Kanai F, Kawakami T, et al. Proteomic analysis of the TGF-beta signaling pathway in pancreatic carcinoma cells using stable RNA interference to silence SMAD4 expression. Biochem Biophys Res Commun 2004; 318: 289-96.
32. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G, Gress TM. TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer 2001; 93: 204-11.
33. Inchovska M, Ogneva V, Martinova Y. Fibroblast growth factors promote pancreatic cell proliferation in normal and STZ-treated hamsters. Arch Med Sci 2006; 2: 90-3.
34. Friess H, Yamanaka Y, Büchler M, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993; 105: 1846-56.
35. Lindemann RK, Nordheim A, Dittmer J. Interfering with TGFbeta-induced Smad3 nuclear accumulation differentially affects TGFbeta-dependent gene expression. Mol Cancer 2003; 2: 20.
36. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-3.
37. Dong C, Zhu S, Wang T, et al. Deficient Smad 7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002; 99: 3908-13.
38. Kleeff J, Maruyama H, Friess H, Büchler MW, Falb D, Korc M. Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem Biophys Res Commun 1999; 255: 268-73.
39. Kleeff J, Ishiwata T, Maruyama H, et al. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 1999; 18: 5363-72.
40. Kracklauer MP, Schmidt C, Sclabas GM. TGFbetal signaling via alphaVbeta6 integrin. Mol Cancer 2003; 2: 28.
41. Bardeesy N, Cheng KH, Berger JH, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 2007; 20: 3130-46.
42. Izeradjene K, Combs C, Best M, et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to include mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 2007; 11: 229-43.
43. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G, Gress TM. TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer 2001; 93: 204-11.
44. Hayes SA, Huang X, Kambhampati S, Platanias LC, Bergan RC. p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion. Oncogene 2003; 22:4841-50.
45. Javelaud D, Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 2005; 24: 5742-50.
46. Ijichi H, Chytil A, Gorska AE, et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 2006; 20: 3147-60.
47. Nakajima S, Doi R, Toyoda E, et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 2004; 10: 4125-33.
48. Birukova AA, Birukov KG, Adyshev D, et al. Involvement of microtubules and Rho pathway in TGF-betal-induced lung vascular barrier dysfunction. J Cell Physiol 2005; 204: 934-47.
49. Qureshi HY, Ahmad R, Sylvester J, Zafarullah M. Requirement of phosphatidylinositol 3-kinase/Akt signaling pathway for regulation of tissue inhibitor of metalloproteinases-3 gene expression by TGF-beta in human chondrocytes. Cell Signal 2007; 19: 1643-51.